Your browser doesn't support javascript.
loading
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.
Fukuzawa, Taku; Sampei, Zenjiro; Haraya, Kenta; Ruike, Yoshinao; Shida-Kawazoe, Meiri; Shimizu, Yuichiro; Gan, Siok Wan; Irie, Machiko; Tsuboi, Yoshinori; Tai, Hitoshi; Sakiyama, Tetsushi; Sakamoto, Akihisa; Ishii, Shinya; Maeda, Atsuhiko; Iwayanagi, Yuki; Shibahara, Norihito; Shibuya, Mitsuko; Nakamura, Genki; Nambu, Takeru; Hayasaka, Akira; Mimoto, Futa; Okura, Yuu; Hori, Yuji; Habu, Kiyoshi; Wada, Manabu; Miura, Takaaki; Tachibana, Tatsuhiko; Honda, Kiyofumi; Tsunoda, Hiroyuki; Kitazawa, Takehisa; Kawabe, Yoshiki; Igawa, Tomoyuki; Hattori, Kunihiro; Nezu, Junichi.
Affiliation
  • Fukuzawa T; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Sampei Z; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Haraya K; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Ruike Y; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Shimizu Y; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Gan SW; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Irie M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Tsuboi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Tai H; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan.
  • Sakiyama T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Sakamoto A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Ishii S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Maeda A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Iwayanagi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Shibahara N; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Shibuya M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Nakamura G; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Nambu T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Hayasaka A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Mimoto F; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Okura Y; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Habu K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Wada M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Miura T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Honda K; Chugai Pharmabody Research Pte. Ltd., 3 Biopolis Drive, #07-11 to 16, Synapse, 138623, Singapore.
  • Tsunoda H; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Igawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Hattori K; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.
  • Nezu J; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
Sci Rep ; 7(1): 1080, 2017 04 24.
Article in En | MEDLINE | ID: mdl-28439081
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement C5 / Antibodies, Neutralizing Limits: Animals / Humans Language: En Journal: Sci Rep Year: 2017 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Complement C5 / Antibodies, Neutralizing Limits: Animals / Humans Language: En Journal: Sci Rep Year: 2017 Document type: Article Affiliation country: Country of publication: